LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 326 participants.

Also called NCT07773051

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 326 participants (planned count) (from the registry)
Sponsor
Longhua Hospital (from the registry)
Registry
  • NCT NCT07773051
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07773051. Randomized; no masking; primary purpose treatment. Start 2025-08-25 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft
Condition
Arteriovenous Graft
Intervention (Device)
LineMatrix® Biological Vascular Graft
Intervention (Device)
GORE-INTERING®
Lead sponsor
Longhua Hospital (class: other)
Collaborator
Humatrix Medical Technology (Suzhou) Co., LTD (class: not stated)

Record details

Record id
cardio:ct-nct07773051
Content hash
fb6a0a64aa68a3fb96330be4ce610609231a09ff4d794ba02846af193d257093